Lenalidomide (CC-5013)

製品コードS1029

Lenalidomide (CC-5013)化学構造

分子量(MW):259.26

Lenalidomide (CC-5013)は一種のTNF-α分泌阻害剤で、PBMCsの中にIC50値が13 nMです。

サイズ 価格(税別)  
JPY 31722.00
JPY 24402.00
JPY 94620.00

カスタマーフィードバック(4)

  • MM1S were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 72 hours. Annexin/PI staining show increased apoptosis associated with caspase 8 and PARP cleavage after 18 and 36 hours of exposure.

    Clin Cancer Res, 2011, 17(10): 3259–71. Lenalidomide (CC-5013) purchased from Selleck.

     

    Effect of lenalidomide treatment (50 mg/kg/day, p.o. for 3 days) on expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), Fas, Fas ligand (FasL), and cleaved caspase-3 in myocardium from lean and ob/ob mice. (a) Representative gel blots of TNF-α, IL-6, Fas, FasL, cleaved caspase-3 and α-Tubulin (as loading control) using specific antibodies. (b) TNF-α.

    Obesity 2012 20, 2174-85. Lenalidomide (CC-5013) purchased from Selleck.

  • MM1S were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 72 hours. Annexin/PI staining show increased apoptosis associated with caspase 8 and PARP cleavage after 18 and 36 hours of exposure. B) MM.1S cells were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 4 hours. Whole lysates were immunoblotted with indicated antibodies

     

     

    Harvard Medical School. Lenalidomide (CC-5013) purchased from Selleck.

    MM.1S cells were cultured for 48 hours in the presence or absence of BMSCs with control media, AT9283, lenalidomide or  AT9283 plus lenalidomide. Cell proliferation was assessed by 3H-TdR uptake (left). MM.1S cells were cultured in the absence or presence of BMSCs and treated for 4 hours with drugs alone or in combination. Whole lysates were immunoblotted with indicated antibodies.

     

     

    Harvard Medical School. Lenalidomide (CC-5013) purchased from Selleck.

製品安全説明書

TNF-alpha阻害剤の選択性比較

生物活性

製品説明 Lenalidomide (CC-5013)は一種のTNF-α分泌阻害剤で、PBMCsの中にIC50値が13 nMです。
ターゲット
TNF-α [1]
(PBMCs)
13 nM
体外試験

Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-κB. [2] Lenalidomide and pomalidomide inhibits autoubiquitination of CRBN in HEK293 T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplifies pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for Lenalidomide resistance in H929 myeloma cell lines is accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and Lenalidomide, CRBN protein is undetectable. [3] Lenalidomide prevents induction of defects by down-regulating tumor cell inhibitory molecule expression. Lenalidomide prevents induction of tumor-induced T cell lytic synapse dysfunction. Lenalidomide treatment blocks CLL cell-induced T cell actin synapse dysfunction, mimicks antibody blockade, and down-regulates expression of CLL inhibitory ligands and their receptors on T cells. Lenalidomide treatment prevents tumor-induced immune suppression in FL, DLBCL, HL, MM, SCC, and OC and down-regulates immunosuppressive ligand expression on all tumor cells examined. CTL killing function significantly increases following antibody blockade of CLL inhibitory ligands or Lenalidomide treatment compared to control treatments. Treatment of autologous CLL-T cell co-cultures with Lenalidomide reverses impaired CD8+ T cell lytic synapse formation and granzyme B trafficking. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LB771-HNC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2S3emlEPTB;Mj6xOVA{QCEQvF2= MlrVV2FPT0WU
L-363 NU\YV|JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PwO2lEPTB;Mj65NlIyOiEQvF2= MmPqV2FPT0WU
JAR MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M363ZmlEPTB;Mj65O|AxOSEQvF2= MV;TRW5ITVJ?
EoL-1-cell Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e0O2lEPTB;ND6xNFUyPSEQvF2= NWC5[ms1W0GQR1XS
BT-549 M3T2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzSTWM2OD14LkKxPFQ6KM7:TR?= NGraVW1USU6JRWK=
SK-NEP-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzmcFlHUUN3ME23Mlg6PTF{IN88US=> NFzBWZlUSU6JRWK=
BV-173 Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PXUWlEPTB;OD62O|U5PSEQvF2= MYTTRW5ITVJ?
HMV-II MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFyLkCxO|Ih|ryP MYHTRW5ITVJ?
HCC1806 Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjyTWM2OD1zMT60OFY4KM7:TR?= M2XPOnNCVkeHUh?=
KASUMI-1 M3vxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf5TWM2OD1zMT61O|Eh|ryP MYHTRW5ITVJ?
SK-MEL-28 MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDVbVJjUUN3ME2xNU46PzZ2IN88US=> MXfTRW5ITVJ?
RPMI-8226 MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PqSmlEPTB;MUKuOlI1OSEQvF2= MoXJV2FPT0WU
T47D MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv4VYFKSzVyPUGzMlIxQTlizszN MXrTRW5ITVJ?
HOP-62 M2DTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH5bYhKSzVyPUGzMlQ5KM7:TR?= Mor5V2FPT0WU
A2058 MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHsfXBKSzVyPUGzMlgyQTlizszN NEjaUphUSU6JRWK=
SW620 M1S3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljSTWM2OD1zND6yOFc{KM7:TR?= NVfWdWpuW0GQR1XS
LCLC-103H NXGxVlZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnBTWM2OD1zND60PFkzKM7:TR?= MWHTRW5ITVJ?
HAL-01 NFfNdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF2LkW3PVYh|ryP MUDTRW5ITVJ?
PANC-08-13 MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrUZ4dGUUN3ME2xOE46OTB6IN88US=> NHPQOGxUSU6JRWK=
COLO-684 MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPifWJKSzVyPUG1MlM6PzlizszN NX3lbVFpW0GQR1XS
DEL MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILSd5FKSzVyPUG1MlQ6QSEQvF2= Moi0V2FPT0WU
K5 NUXjOmRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYi4bG1LUUN3ME2xOk4yPDh4IN88US=> NFXTe29USU6JRWK=
SK-MEL-24 M2T6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHF[m8{UUN3ME2xOk41PjV{IN88US=> NHHyTWtUSU6JRWK=
ACN MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELMfoVKSzVyPUG2MlUzQTdizszN MlGzV2FPT0WU
H9 M{jnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTncHFMUUN3ME2xOk43OjZizszN NV;XRm1vW0GQR1XS
EM-2 MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L4bmlEPTB;MUeuNVQ{KM7:TR?= MXPTRW5ITVJ?
HSC-4 NVrYfIJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIG3b4lKSzVyPUG3MlY3ODFizszN NHWwTmpUSU6JRWK=
IGROV-1 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTF5Lke4N{DPxE1? MVnTRW5ITVJ?
TE-1 NGWwdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknJTWM2OD1zNz65PVY5KM7:TR?= M2XPZXNCVkeHUh?=
LN-405 NYDUUlByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\wcmlEPTB;MUmuPVA4PiEQvF2= NYrNTVRuW0GQR1XS
MSTO-211H NG\JVo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJyLkO1O|Mh|ryP NHf6UJpUSU6JRWK=
MOLT-4 M1jr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHWPW9vUUN3ME2yNE42PzV7IN88US=> M3LLXnNCVkeHUh?=
RS4-11 NXfkNGNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJ{LkG1OlMh|ryP NUHo[lRPW0GQR1XS
ES3 M{S3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJ{Lk[5OlMh|ryP MWLTRW5ITVJ?
SBC-1 NIDpNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXPTWM2OD1{Mz64Olk3KM7:TR?= NVjJT5FkW0GQR1XS
CTV-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLvNJRzUUN3ME2yOU4xOTR7IN88US=> M2XvUHNCVkeHUh?=
HuP-T3 M2qxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LHN2lEPTB;MkWuOFAxQSEQvF2= M{\SbXNCVkeHUh?=
HCC2218 M2[1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3ZTWM2OD1{NT61OFA4KM7:TR?= M{m1Z3NCVkeHUh?=
HDLM-2 M3S4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[zTWM2OD1{OD6yNFI3KM7:TR?= M1zFOXNCVkeHUh?=
ABC-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr3TWM2OD1{OT62PVc1KM7:TR?= M1LrNHNCVkeHUh?=
MV-4-11 Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPETWM2OD1{OT63N|E4KM7:TR?= MUfTRW5ITVJ?
WM-115 NYPzZppJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTNyLkOwPVkh|ryP NFzkV|dUSU6JRWK=
SW1990 M1;Scmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nt[GlEPTB;M{CuN|Mh|ryP NUe2OWR[W0GQR1XS
HCC70 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXGTWM2OD1|MD63N|Q3KM7:TR?= NIC1WmJUSU6JRWK=
KYSE-520 M4\DNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X1[2lEPTB;M{CuPFg{QSEQvF2= MWfTRW5ITVJ?
JEG-3 M4Hvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTNzLkG2NVQh|ryP MkjZV2FPT0WU
C8166 M2jyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTNzLkKyO|Qh|ryP NHHOTmlUSU6JRWK=
SK-OV-3 NUHpOZRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHVNmdtUUN3ME2zNU43PzV3IN88US=> MUjTRW5ITVJ?
NCI-H526 NY\PdnMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTN{Lk[4N{DPxE1? MmfLV2FPT0WU
NKM-1 MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnnS2JKSzVyPUOyMlk2PjhizszN MoruV2FPT0WU
ECC10 M4XjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTN2Lke0OFMh|ryP NX72fYNJW0GQR1XS
A2780 M4S4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTN3LkO2NFEh|ryP MWPTRW5ITVJ?
KY821 NEeyZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrwPGlKSzVyPUO1Mlc3QDFizszN NXHlOXJSW0GQR1XS
MKN1 MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTN4LkKxN|ch|ryP M4rue3NCVkeHUh?=
EKVX NULPN4VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrWcW5KSzVyPUO3MlQzOTJizszN MU\TRW5ITVJ?
EW-16 M4LUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTN6LkO4PFUh|ryP MUfTRW5ITVJ?
CTB-1 NVrYNXFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHuyPY5KSzVyPUO5Mlc4QDlizszN M3PCfHNCVkeHUh?=
COR-L105 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTRyLkS3OFYh|ryP MWrTRW5ITVJ?
NCI-SNU-5 NH7ifXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLITWM2OD12MT6yNFY6KM7:TR?= NH;YbpNUSU6JRWK=
Mewo NG\kPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGryUGdKSzVyPUSxMlk5PzFizszN NUjZephIW0GQR1XS
BCPAP NWG1eJB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3FTWM2OD12Mz63PVE4KM7:TR?= MUfTRW5ITVJ?
KARPAS-45 M13Rfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T1SmlEPTB;NESuNlc4PiEQvF2= MXXTRW5ITVJ?
NCI-H1693 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTSXJZ[UUN3ME20Ok43QTh4IN88US=> MoK5V2FPT0WU
H-EMC-SS NELlSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTtdldKSzVyPUS4MlMzOjRizszN MXHTRW5ITVJ?
697 NEXVR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILh[YRKSzVyPUWwMlM2PDVizszN M33MeXNCVkeHUh?=
KP-N-YS Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL6T4lKSzVyPUWyMlMyPDJizszN NF3oTVJUSU6JRWK=
NCI-H1304 M1XGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[xTo5KSzVyPUWyMlcxOjRizszN NFfaRpJUSU6JRWK=
NOS-1 NHPvUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT2TWM2OD13Mj64OVU6KM7:TR?= M1;qW3NCVkeHUh?=
NCI-H2342 NHjWeZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTV|LkC1NFgh|ryP MWDTRW5ITVJ?
KYSE-270 M{e3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LyVmlEPTB;NUOuOlM3PCEQvF2= MXrTRW5ITVJ?
LU-135 NEO5bIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O2cmlEPTB;NUWuNVg2OyEQvF2= MmH3V2FPT0WU
OE33 Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTV3LkixPEDPxE1? NIPqN3VUSU6JRWK=
ML-2 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvaWZBlUUN3ME21OU46PDh7IN88US=> M2D5O3NCVkeHUh?=
KMOE-2 M3fEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NISz[HdKSzVyPUW2MlI5QTNizszN NXm4U3ZjW0GQR1XS
Daoy M33zWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnER2tnUUN3ME21Ok4{OjB2IN88US=> M2DEbnNCVkeHUh?=
KNS-62 Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;FeWlEPTB;NUeuNFE1OiEQvF2= NX32UmhmW0GQR1XS
NBsusSR M{DYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXz[lBKSzVyPUW3MlU4ODVizszN M{jh[HNCVkeHUh?=
UACC-257 M4npbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTV6Lk[yOlQh|ryP Mlm2V2FPT0WU
LU-139 NWPkPXdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXMfZlKSzVyPUW4MlgzPiEQvF2= NWrxeZQzW0GQR1XS
CAL-85-1 M1\XUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPrbWVKSzVyPUW4Mlg3PDNizszN M1f2bHNCVkeHUh?=
NCI-H720 NYnKUWRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTMUWVrUUN3ME21PE45QTR{IN88US=> NHf6botUSU6JRWK=
MLMA NGDUZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTV7LkC5NUDPxE1? NInPVYVUSU6JRWK=
A3-KAW MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:wNItKSzVyPUW5MlI5ODlizszN M4f1bnNCVkeHUh?=
Ramos-2G6-4C10 Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnVbmdKSzVyPUW5MlYzQDdizszN NFz5emZUSU6JRWK=
A388 M{nRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TRT2lEPTB;NkCuOFQ6KM7:TR?= NYPIN5RpW0GQR1XS
LAMA-84 M3\kSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf4TWM2OD14MD65PVA2KM7:TR?= NW\GNIJtW0GQR1XS
GCT M3\0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTZzLkC3PFYh|ryP MXLTRW5ITVJ?
K-562 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTZzLkWzN|Mh|ryP NU\sOZVrW0GQR1XS
NCI-H1666 M3Xu[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HFXGlEPTB;NkGuPFc2KM7:TR?= MkjSV2FPT0WU
NCI-H1993 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu2TWM2OD14Mz60NFQ{KM7:TR?= MXTTRW5ITVJ?
NCI-H358 MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HCSWlEPTB;NkWuNFEzOSEQvF2= MWnTRW5ITVJ?
NB6 MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:0cmlEPTB;NkWuPVg5KM7:TR?= MmXrV2FPT0WU
HCE-T MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj2TWM2OD14Nz6wO|k5KM7:TR?= MVjTRW5ITVJ?
DOK MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrMTWM2OD14Nz60PVQ5KM7:TR?= MYjTRW5ITVJ?
HT-1376 NUDqdHVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTZ7LkizNVQh|ryP MkXhV2FPT0WU
NEC8 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrXTWM2OD15MD6xNlQ{KM7:TR?= M4LWc3NCVkeHUh?=
G-402 MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPvXpBtUUN3ME23NE46Ozl3IN88US=> MkS3V2FPT0WU
GR-ST NWLnd29pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HKVGlEPTB;N{GuNVczKM7:TR?= NHG5V|hUSU6JRWK=
QIMR-WIL NVLIUHFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[wXoxQUUN3ME23NU41PDN2IN88US=> MYjTRW5ITVJ?
CHP-212 M1HycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7tSXpKSzVyPUexMlk3PSEQvF2= MnHlV2FPT0WU
KU812 MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC2TWM2OD15Mj65O|AzKM7:TR?= MX\TRW5ITVJ?
Becker M{LUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r3N2lEPTB;N{OuNVQ5QSEQvF2= NVzQUFJ5W0GQR1XS
ChaGo-K-1 NVLsR5lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M363SGlEPTB;N{SuO|Q5PiEQvF2= NGTBc3JUSU6JRWK=
A498 M3\VTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTd2LkmzNFgh|ryP MkDWV2FPT0WU
NCI-H69 M1flZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFT6OodKSzVyPUe1Mlc3PjNizszN M3TEOHNCVkeHUh?=
NCI-H209 NFriXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PHc2lEPTB;N{iuOlE1PyEQvF2= MYHTRW5ITVJ?
CAL-33 MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PpfWlEPTB;N{iuPVk{QSEQvF2= NXjWcXlOW0GQR1XS
COLO-680N MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nSO2lEPTB;N{muNVAxPyEQvF2= M1nMcHNCVkeHUh?=
D-283MED NI[x[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G4PGlEPTB;N{muPFEzKM7:TR?= NXTIWZJqW0GQR1XS
ATN-1 NF7ocVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DYOmlEPTB;OEGuNVE5PyEQvF2= Ml36V2FPT0WU
NCI-N87 NFGzTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDvdoJKSzVyPUixMlczQTZizszN NE\SXoxUSU6JRWK=
MHH-NB-11 M1y1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRThzLki4OFkh|ryP NF;nSXNUSU6JRWK=
HEL NFnJTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLCTWM2OD16Mj60NVM1KM7:TR?= MU\TRW5ITVJ?
NB69 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLkTWM2OD16Mz6wNFM{KM7:TR?= MojOV2FPT0WU
MPP-89 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv4b3RrUUN3ME24N{4zPTd3IN88US=> M17FZnNCVkeHUh?=
COLO-829 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTh3LkS5NVIh|ryP MYrTRW5ITVJ?
ONS-76 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTh3Lke5NFgh|ryP NGSxd29USU6JRWK=
EW-3 M1vnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G0c2lEPTB;OE[uNlA{OiEQvF2= Mn;RV2FPT0WU
EW-11 Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Dx[WlEPTB;OE[uOFM{PiEQvF2= M{\IbHNCVkeHUh?=
SW900 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjnS45KSzVyPUi3MlIxPTNizszN M4XHOXNCVkeHUh?=
MOLT-13 M3v0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTh5LkKyOFMh|ryP M1LnOXNCVkeHUh?=
HuP-T4 NYHuWpFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn3W|RKSzVyPUmxMlA1ODVizszN MofkV2FPT0WU
HCC1419 NX7OT|lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnuemhKSzVyPUmxMlY{PzRizszN NXvkWVJrW0GQR1XS
CAL-72 NFPWTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEm5fHVKSzVyPUmyMlAzOTlizszN M3\3c3NCVkeHUh?=
Mo-T MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\obGlEPTB;OUKuO|Y6PyEQvF2= NGDWcmpUSU6JRWK=
OC-314 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LCb2lEPTB;OUKuPFgzOSEQvF2= NX3Zc2VkW0GQR1XS
BHT-101 NFXSS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHGVIRKSzVyPUmzMlEh|ryP M4HRTHNCVkeHUh?=
EW-18 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofnTWM2OD17Mz64OFYzKM7:TR?= M{KyTHNCVkeHUh?=
TE-12 M1;KfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHiem11UUN3ME25OE4{ODV3IN88US=> MWLTRW5ITVJ?
MDA-MB-361 NEfJSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDrPYRTUUN3ME25Ok4xPTF4IN88US=> NVrvd5NbW0GQR1XS

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The induction of angiogenesis by bFGF is significantly inhibited by oral treatment of Lenalidomide in a dose-dependent manner. Lenalidomide significantly decreases the percentage of vascularized area from 5.16% (control group) to 2.58% (50 mg/kg). Lenalidomide significantly reduces the calculated total MVL from 21.07 (control) to 8.11 (50 mg/kg). Lenalidomide significantly inhibites HUVEC migration through the fibronectin-coated membranes towards 0.1 ng/mL of bFGF at 100 μM, 1 ng/mL of VEGF at concentrations of 10 μM and 100 μM. [5]

お薦めの試験操作(参考用のみ)

動物試験:

[5]

+ 展開
  • 動物モデル: Adult male Sprague-Dawley rats bearing HUVECs cells
  • 製剤: 0.5% DMSO
  • 投薬量: 50 mg/kg and 250 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 52 mg/mL (200.57 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
30% PEG 400+0.5% Tween 80+5% propylene glycol+H2O
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 259.26
化学式

C13H13N3O3

CAS No. 191732-72-6
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02871219 Recruiting Follicular Lymphoma M.D. Anderson Cancer Center|Genentech, Inc. December 6, 2016 Phase 2
NCT00540007 Completed Hodgkin Disease Washington University School of Medicine|Celgene Corporation September 6, 2007 Phase 2
NCT01629082 Completed Myeldysplastic Syndrome (MDS)|Chronic Myelomonocytic Leukemia|Bone Marrow Diseases|Neutropenia|Acute Myeloid Leukemia (AML) National Heart, Lung, and Blood Institute (NHLBI)|Celgene Corporation|National Institutes of Health Clinical Center (CC) June 5, 2012 Phase 1
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT02225275 Recruiting Leukemia M.D. Anderson Cancer Center|Genentech, Inc.|Celgene Corporation March 31, 2016 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    What is the formulation for mouse injection(i.p.)?

  • 回答:

    This paper has the information you need: http://link.springer.com/article/10.1208/s12248-012-9401-2. Add lenalidomide to the appropriate volume of sterile phosphate-buffered saline (PBS) containing 1% hydrochloric acid (HCl). the pH of this preparation was adjusted to 7.0–7.6 using sodium hydroxide and sterile filtered using a 0.22 μm Steriflip filter.

  • 問題2:

    what is the procedure to resuspend this compound?

  • 回答:

    You can resuspend this compund by DMSO, the solubility is about 52 mg/mL (200.57 mM). For in vivo study, you can prepare the working solution with the vehicle of: 30% PEG400/0.5% Tween80/5% propylene glycol for oral administration.

Related Antibodies

TNF-alpha信号経路図

TNF-alpha Inhibitors with Unique Features

相関TNF-alpha製品

Tags: Lenalidomide (CC-5013)を買う | Lenalidomide (CC-5013) ic50 | Lenalidomide (CC-5013)供給者 | Lenalidomide (CC-5013)を購入する | Lenalidomide (CC-5013)費用 | Lenalidomide (CC-5013)生産者 | オーダーLenalidomide (CC-5013) | Lenalidomide (CC-5013)化学構造 | Lenalidomide (CC-5013)分子量 | Lenalidomide (CC-5013)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID